Abstract 2454: A Drug Response Predictor (DRP®) is associated with enhanced overall survival in the phase 2 trial in advanced, recurrent ovarian cancer patients treated twice daily with 2X-121/ Stenoparib (NCT03878849)
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: OU Health Stephenson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148782786
Cites:
Cited by:
Related to: